BI-2545 is a potent autotaxin (ATX) inhibitor that significantly reduces LPA, with IC 50 s of 2.2 nM and 3.4 nM for human ATX and rat ATX, respectively In Vitro BI-2545 displays good potency in the LPA and rat whole blood assay with IC 50 s of 29 nM and 96 nM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo BI-2545 (10 mg/kg; p.o.) has high and sustained in vivo efficacy in reducing LPAs . BI-2545 (10 mg/kg; p.o.) has a half-life of t 1/2 =3.4 hours . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rat Dosage: 10 mg/kg Administration: Oral administration Result: Reduces the sum of the plasma LPA species up to 90%. Form:Solid IC50& Target:C50: 2.2 nM (human ATX), 3.4 nM (rat ATX)
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
BI-2545
CAS number：2162961-71-7 molecular formula：C23H19F6N5O3
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 2162961-71-7 | molecular formula | C23H19F6N5O3 |
| molecular weight | 527.42 g/mol | Exact mass | ≥99% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
